Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) – Pipeline Review, H2 2016’, provides in depth analysis on Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted pipeline therapeutics.

The report provides comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects

The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Jyant Technologies Inc

NeuroNano Pharma Inc

Neurotez Inc

Novelion Therapeutics Inc

XL-protein GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Overview 7

Therapeutics Development 8

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Stage of Development 8

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Therapy Area 9

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Indication 10

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Companies 13

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development 22

Jyant Technologies Inc 22

NeuroNano Pharma Inc 23

Neurotez Inc 24

Novelion Therapeutics Inc 25

XL-protein GmbH 26

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles 27

CV-0801 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CV-0802 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

memtin - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

metreleptin - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Synthetic Peptide to Agonize Leptin Receptor for Diabetes and Obesity - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

XL-100 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Projects 40

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products 42

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Featured News & Press Releases 43

Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy 43

Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 44

Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin 45

Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin 45

May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy 46

Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy 47

Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer’s Disease 47

Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy 48

Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy 49

Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy 50

Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy 51

Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy 52

Nov 16, 2010: Juvenile Diabetes Research Foundation And Amylin Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Jyant Technologies Inc, H2 2016 22

Pipeline by NeuroNano Pharma Inc, H2 2016 23

Pipeline by Neurotez Inc, H2 2016 24

Pipeline by Novelion Therapeutics Inc, H2 2016 25

Pipeline by XL-protein GmbH, H2 2016 26

Dormant Projects, H2 2016 40

Dormant Projects (Contd..1), H2 2016 41

Discontinued Products, H2 2016 42

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports